{"id":303530,"date":"2023-12-13T14:32:18","date_gmt":"2023-12-13T20:32:18","guid":{"rendered":"https:\/\/www.liveaction.org\/news\/?p=303530"},"modified":"2023-12-13T14:33:08","modified_gmt":"2023-12-13T20:33:08","slug":"us-supreme-court-case-regulation-abortion-pill","status":"publish","type":"post","link":"https:\/\/archive.liveaction.org\/news\/us-supreme-court-case-regulation-abortion-pill\/","title":{"rendered":"US Supreme Court will hear case regarding regulation of abortion pill"},"content":{"rendered":"
<\/div>

The Supreme Court has announced<\/a> that it will hear the case involving abortion pill restrictions this term \u2014 its first case involving abortion since Roe v. Wade<\/em> was overturned in 2022.<\/p>\n

In August, the U.S. Court of Appeals for the Fifth Circuit ruled<\/a> that mifepristone can remain on the market in Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration<\/a><\/em> \u2014 but only under the conditions for use from 2016. The Food and Drug Administration (FDA) expanded<\/a> the safety requirements (REMS) for mifepristone several times; in 2021, the FDA allowed for mail-order pharmacy distribution, enabling it to be shipped by mail, and eliminating the requirement for it to be dispensed in-person. In 2023, the FDA allowed<\/a> the abortion pill to be sold at retail pharmacies.<\/p>\n

Though the court had called for the prior safety standards to be reinstated, the ruling did not have an immediate impact on the availability of mifepristone, due to a prior order<\/a> from the Supreme Court that would stay in effect until the Court rules again on the issue or refuses to hear the case on appeal.<\/p>\n

The FDA then requested<\/a> the Supreme Court’s intervention. Danco, the manufacturer of the abortion pill, also asked for the high court to weigh in.<\/p>\n

Oral arguments will likely take place in the spring, with a decision expected to come in June. The justices said they would not consider a separate challenge to the FDA’s initial approval of mifepristone in 2000, meaning whatever decision the Supreme Court makes, mifepristone will<\/strong> remain available. It’s been estimated that since being approved, approximately 6 million preborn children<\/a> have been killed.<\/p>\n